Investigating interleukin-37 as a treatment and biomarker for Alzheimer’s disease

研究白细胞介素 37 作为阿尔茨海默病的治疗方法和生物标志物

• 批准号: nhmrc : GNT1129192
• 负责人: Dr Rodrigo Medeiros
• 金额: $ 67.79万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/investigating-interleukin-37-alzheimers-disease/1347741
• 关键词: Investigating; interleukin; 37; treatment; biomarker

Alzheimer’s disease (AD) is the defining healthcare condition of our generation. Finding asymptomatic at risk individuals at preclinical stages will allow initiation of therapies that will either slow or, preferably, stop the progression of the disease. Herein, we will study a protein called interleukin-37 as an early biomarker and treatment for AD.

阿尔茨海默病（AD）是我们这一代人的定义医疗条件。在临床前阶段发现无症状的风险个体将允许开始减缓或优选地停止疾病进展的治疗。在此，我们将研究一种称为白细胞介素-37的蛋白质作为AD的早期生物标志物和治疗方法。